The European Medicines Agency is this week due to decide whether to recommend EU-wide marketing approval for 13 products, including AstraZeneca/Sanofi’s long-acting monoclonal antibody, nirsevimab, for immunizing infants to prevent lower respiratory tract infection caused by the respiratory syncytial virus (RSV).
Nirsevimab was accepted onto the EMA’s PRIME scheme (which is designed to help companies with their development plans for products...








